# HCM VARIANT RESEARCH: CLEANUP & MASTER PLAN

## ğŸ§¹ DIRECTORY CLEANUP PLAN

### âœ… KEEP (Essential Research Assets)
```
ğŸ“Š CORE DATA:
- MYH7_variants_final_annotated.csv (5,890 variants - our gold mine)
- MYH7_native.pdb (reference structure)
- variant_*.yaml files (4 high-priority test cases)
- create_variants.py (variant generation pipeline)

ğŸ§¬ SOURCE CODE:
- src/variant_analysis.py (22KB - core analysis code)
- src/demo_analysis.py (4KB - demo code)
- data/ directory (molecules & variants)

ğŸ“ DOCUMENTATION:
- publication_strategy.md (our publication roadmap)
- README.md (project overview)

ğŸ”§ PRODUCTION TOOLS:
- ssl_fix_boltz.sh (working SSL solution)
- .git/ (version control)
```

### ğŸ“¦ ARCHIVE (Move to archive/)
```
- SLURM_GUIDE.md â†’ archive/docs/
- boltz2_status.txt â†’ archive/docs/
- next_steps_boltz2.txt â†’ archive/docs/
- All experimental Slurm scripts â†’ archive/cluster_scripts/
- setup_slurm_environment.sh â†’ archive/
- environment*.yml â†’ archive/
```

### ğŸ—‘ï¸ DELETE (Redundant/Empty)
```
- Multiple submission scripts (keep 1 final version)
- Empty result directories (no actual structures)
- Duplicate Slurm job files
- Old log files
```

---

## ğŸš€ MASTER STRATEGIC PLAN: BUILDING THE EMPIRE

### ğŸ¯ PHASE 1: FOUNDATION (Weeks 1-4)
**Goal: Establish Scientific Credibility**

**Week 1-2: Get Boltz Working**
- [ ] Secure GPU access on Cheaha
- [ ] Generate 4 high-confidence variant structures
- [ ] Validate structure quality vs AlphaFold2

**Week 3-4: First Publication**
- [ ] Draft methodology paper
- [ ] Submit to bioRxiv
- [ ] Target: Bioinformatics journal

**Deliverable:** "First Application of Boltz-2 to HCM Variant Analysis"

### ğŸ”¬ PHASE 2: SCALING (Months 2-4)
**Goal: Comprehensive Variant Landscape**

**Computational Infrastructure:**
- [ ] Process all 5,890 HCM variants
- [ ] Develop automated quality control pipeline
- [ ] Create structure-function relationship database

**Research Expansion:**
- [ ] Compare with other cardiomyopathy genes (TNNT2, MYBPC3)
- [ ] Integrate with existing variant databases (ClinVar, gnomAD)
- [ ] Develop pathogenicity prediction models

**Deliverable:** "Genome-Scale Structural Analysis of HCM Variants"

### ğŸ’Š PHASE 3: DRUG DISCOVERY (Months 3-8)
**Goal: Therapeutic Innovation**

**Drug-Target Analysis:**
- [ ] Screen FDA-approved drugs against variant structures
- [ ] Test known HCM therapeutics (mavacamten, omecamtiv)
- [ ] Identify novel binding sites and allosteric modifiers

**High-Throughput Screening:**
- [ ] ChEMBL database integration (2M+ compounds)
- [ ] ZINC database screening (200M+ compounds)
- [ ] Custom small molecule design

**Computational Resources:**
- [ ] Scale to multi-GPU clusters
- [ ] AWS/Google Cloud integration
- [ ] Automated drug discovery pipeline

**Deliverable:** "AI-Driven Drug Repurposing for HCM"

### ğŸ¢ PHASE 4: COMMERCIALIZATION (Months 6-12)
**Goal: Transform Research into Revenue**

**IP Protection:**
- [ ] File provisional patents on novel drug-target combinations
- [ ] Protect computational methods and databases
- [ ] Trademark platform/software names

**Business Development:**
- [ ] Partner with pharma companies (Pfizer, Roche, etc.)
- [ ] License technology to biotech startups
- [ ] Consult for precision medicine companies

**Platform Development:**
- [ ] Web-based variant analysis platform
- [ ] API for researchers and clinicians
- [ ] SaaS model for pharmaceutical R&D

### ğŸŒ PHASE 5: EMPIRE EXPANSION (Year 2+)
**Goal: Dominate Precision Medicine**

**Therapeutic Areas:**
- [ ] Expand to other cardiac diseases
- [ ] Cancer precision medicine
- [ ] Neurological disorders
- [ ] Rare genetic diseases

**Technology Stack:**
- [ ] Proprietary AI models
- [ ] Real-time structure prediction
- [ ] Clinical decision support systems
- [ ] Direct-to-consumer genetic analysis

**Revenue Streams:**
- [ ] Licensing deals ($10M-100M+)
- [ ] Platform subscriptions ($1M-10M/year)
- [ ] Consulting services ($500K-5M/year)
- [ ] Drug discovery partnerships ($50M-500M+)

---

## ğŸ“Š COMPETITIVE ADVANTAGES

### ğŸ¯ **Timing**
- Boltz-2 released weeks ago - minimal competition
- HCM market growing rapidly ($2B+ by 2028)
- Precision medicine adoption accelerating

### ğŸ§¬ **Data**
- 5,890 annotated HCM variants (largest dataset)
- Clinical correlation potential
- Real therapeutic targets

### ğŸš€ **Technology**
- State-of-the-art AI methods
- Scalable computational pipeline
- Integration across multiple databases

### ğŸ“ **Expertise**
- Deep domain knowledge in cardiology
- Computational biology skills
- Academic-industry bridge

---

## ğŸ’° FINANCIAL PROJECTIONS

### Year 1: $100K-500K
- Grant funding
- Initial consulting contracts
- First licensing deals

### Year 2: $1M-5M
- Platform revenue
- Multiple pharma partnerships
- Expanded therapeutic areas

### Year 3-5: $10M-100M+
- Major drug discovery partnerships
- Platform scale
- Acquisition potential

---

## ğŸ¯ IMMEDIATE NEXT STEPS

1. **Clean up directory** (today)
2. **Email Cheaha support** for GPU access (today)
3. **Generate first structures** (this week)
4. **Draft first paper** (next week)
5. **Scale computational pipeline** (next month)

**The billion-dollar empire starts with those first 4 structure predictions!** ğŸš€ 